Hologic Inc. (HOLX)

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

HOLX's Genius digital cytology system and global rollout position its Cytology unit for long-term growth despite near-term headwinds.

Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

HOLX targets a mid-single-digit organic growth rebound in 2026, powered by Breast Health recovery and new product innovation.

HOLX's Diagnostics arm eyes long-term growth with new assays, platform expansion and oncology test adoption despite headwinds.

HOLX rises post earnings beat, fueled by Diagnostics strength and Surgical growth. However, macro headwinds persist.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

HOLX posts better-than-expected Q3 results, but margin contraction and regional headwinds pressure investor sentiment.